Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

HLA-DRB1 anticorps

HLA-DRB1 Reactivité: Humain, Singe WB, FACS, IF, IHC, ISt, StM Hôte: Souris Monoclonal LN-3 unconjugated
N° du produit ABIN6939640
  • Antigène Voir toutes HLA-DRB1 Anticorps
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR beta 1 (HLA-DRB1))
    Reactivité
    • 95
    • 30
    • 11
    • 11
    • 11
    • 11
    • 10
    • 8
    Humain, Singe
    Hôte
    • 54
    • 42
    Souris
    Clonalité
    • 53
    • 43
    Monoclonal
    Conjugué
    • 41
    • 9
    • 8
    • 6
    • 5
    • 3
    • 3
    • 3
    • 3
    • 3
    • 3
    • 3
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Cet anticorp HLA-DRB1 est non-conjugé
    Application
    • 61
    • 45
    • 38
    • 25
    • 18
    • 17
    • 13
    • 8
    • 4
    • 3
    • 2
    • 1
    • 1
    • 1
    • 1
    Western Blotting (WB), Flow Cytometry (FACS), Immunofluorescence (IF), Immunohistochemistry (IHC), Immunostaining (ISt), Staining Methods (StM)
    Specificité
    This MAb reacts with a 28 kDa chain of HLA-DRB1 antigen, a member of MHC class II molecules. It does not cross react with HLA-DP and HLA-DQ. The L243 antibody recognizes a different epitope than the LN3 monoclonal antibody, and these antibodies do not cross-block binding to each other's respective epitopes. HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kDa alpha (heavy) chain and a 28 kDa beta (light) chain. It is expressed on B-cells, activated T-cells, monocytes/macrophages, dendritic cells and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 Molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells. It is an excellent histiocytic marker in paraffin sections producing intense staining. True histiocytic neoplasms are similarly positive. HLA-DR antigens also occur on a variety of epithelial cells and their corresponding neoplastic counterparts. Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma.
    Aucune reactivité croisée
    Souris
    Purification
    Purified by Protein A/G
    Immunogène
    Activated human peripheral blood mononuclear cells
    Clone
    LN-3
    Isotype
    IgG2b kappa
    Top Product
    Discover our top product HLA-DRB1 Anticorps primaire
  • Indications d'application

    Positive Control: Raji, Ramos, Daudi or HuT78 cells. Spleen, Tonsil or lymph node.

    Known Application: Flow Cytometry (1-2 μg/million cells), Immunofluorescence (1-2 μg/mL), Western Blot (1-2 μg/mL), Immunohistochemistry (Formalin-fixed) (0.5-1.0 μg/mL for 30 minutes at RT)(Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 10 mM Citrate Buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes)Optimal dilution for a specific application should be determined.

    Restrictions
    For Research Use only
  • Concentration
    200 μg/mL
    Buffer
    10 mM PBS with 0.05 % BSA & 0.05 % azide.
    Agent conservateur
    Sodium azide
    Précaution d'utilisation
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Stock
    4 °C,-80 °C
    Stockage commentaire
    Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.
    Date de péremption
    24 months
  • Antigène
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR beta 1 (HLA-DRB1))
    Autre désignation
    HLA-DRB1 (HLA-DRB1 Produits)
    Synonymes
    anticorps MGC108235, anticorps DRB1, anticorps DRw10, anticorps HLA-DR1B, anticorps HLA-DRB, anticorps SS1, anticorps major histocompatibility complex, class II, DR beta 1, anticorps hla-drb1, anticorps HLA-DRB1
    Poids moléculaire
    28kDa (beta chain)
    ID gène
    3123
    UniProt
    P01911
    Pathways
    TCR Signaling, Positive Regulation of Peptide Hormone Secretion, Production of Molecular Mediator of Immune Response, CXCR4-mediated Signaling Events, Cancer Immune Checkpoints
Vous êtes ici:
Support technique